(San Francisco Business Times subscription required.)
Two projects — including one aimed at developing an artificial pancreas that would eliminate daily injections by diabetes patients — garnered funding from health care giant Johnson & Johnson to turn science ideas into companies.
The projects are the first Bridging the Gap Awards supported by J&J through a program with the California Institute for Quantitative Biosciences, or QB3.
The awards of up to $250,000 over two years are meant to give researchers at the University of California, San Francisco, UC Berkeley and UC Santa Cruz funding to prove that their projects are viable. The ultimate goal is to form companies around those projects, said Neena Kadaba, QB3’s director of industry alliances.